Calcipotriol as a daylight photodynamic therapy enhancer: a case-control study

Area of Science:

• Dermatology
• Oncology
• Photomedicine

Background:

• Actinic keratoses (AKs) are common, sun-induced skin lesions.
• AKs are recognized precursors to squamous cell carcinomas (SCCs).
• Current treatments for AKs have varying efficacy and side effect profiles.

Purpose of the Study:

• To evaluate the efficacy of combining calcipotriol (CAL) ointment pre-treatment with daylight photodynamic therapy (DL-PDT) for AKs.
• To assess the impact of CAL pre-treatment on AK lesion severity and clearance.
• To determine the safety and tolerability of the combined treatment regimen.

Main Methods:

• An observational case-control study involving 20 male patients with grade I-II AKs.
• Patients were randomized into a case group (CAL ointment + DL-PDT) and a control group (moisturizer + DL-PDT).
• Treatment involved 14 days of CAL pre-treatment followed by three DL-PDT sessions, with assessments using the Actinic Keratosis Area Severity Index (AKASI) at baseline, 3, and 6 months.

Main Results:

• The CAL pre-treatment group showed a statistically significant reduction in AKASI scores compared to the control group.
• Enhanced clearance of actinic keratoses was observed with the CAL + DL-PDT combination.
• The combined treatment was well-tolerated with minimal adverse effects reported.

Conclusions:

• Calcipotriol ointment pre-treatment enhances the efficacy of daylight photodynamic therapy for actinic keratoses.
• This combined approach offers an effective and safe strategy for managing AKs.
• The findings suggest potential for preventing AK progression to squamous cell carcinoma.